Outer membrane vesicles of the VA‐MENGOC‐BC® vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two‐dimensional gel electrophoresis and mass spectrometry

@article{Uli2006OuterMV,
  title={Outer membrane vesicles of the VA‐MENGOC‐BC{\textregistered} vaccine against serogroup B of Neisseria meningitidis: Analysis of protein components by two‐dimensional gel electrophoresis and mass spectrometry},
  author={Liliam Uli and Lila R Castellanos-Serra and Lazaro Hiram Betancourt and Francisco Dom{\'i}nguez and Ram{\'o}n Barber{\'a} and Franklin Sotolongo and Gerardo Guill{\'e}n and Rolando Paj{\'o}n Feyt},
  journal={PROTEOMICS},
  year={2006},
  volume={6}
}
Neisseria meningitidis is a Gram‐negative bacterium responsible for significant mortality worldwide. While effective polysaccharides‐based vaccines exist against serogroups A, C, W135, and Y, no similar vaccine is suitable for children under 4 years against disease caused by serogroup B strains. Therefore, major vaccine efforts against this serogroup are based on outer membrane vesicles (OMVs), containing major outer membrane proteins. The OMV‐based vaccine produced by the Finlay Institute in… Expand
Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media.
TLDR
The high resolution two-dimensional separation of the OMVs on a large-format gel across a pH range of 3-11 resolved around 2000 protein spots from which 75 proteins were identified by mass spectrometry. Expand
Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
TLDR
There is good reason to believe that in the coming few years the "OMV-concept" will be exploited further and that a number of cross-protective "universal" antigens will be included in vaccines against serogroup B meningococcal disease. Expand
A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV-based vaccine against N. meningitidis serogroup B and C
ABSTRACT The protein composition of an Outer Membrane Vesicle (OMV) preparation that constitutes the active pharmaceutical ingredient of VA-MENGOC-BC®, an effective vaccine against NeisseriaExpand
Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens.
TLDR
Human volunteers vaccinated with experimental Neisseria meningitidis serogroup B vaccines based on strain H44/76 detoxified L3 lipooligosaccharide (LOS)-derived outer membrane vesicles or the licensed Cuban vaccine, VA-MENGOC-BC were vaccinated with an immuno-proteomic approach to identify potential targets of cross-bactericidal antibodies using an L2-LOS derived OMV preparation. Expand
Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
TLDR
The results suggest that NMB0928, one of those proteins present in the OMVs, is a novel antigen worth to be included in a broadly protective meningococcal vaccine. Expand
Proteomic study via a non-gel based approach of meningococcal outer membrane vesicle vaccine obtained from strain CU385: A road map for discovering new antigens
TLDR
This work presents the results from a study of the protein composition of outer membrane vesicles from VA-MENGOC-BC® (Finlay Institute, Cuba), an available vaccine against serogroup B Neisseria meningitidis, providing a detailed description of the vaccine. Expand
Immunogenicity profiling of protein antigens from capsular group B Neisseria meningitidis
TLDR
The relative dominance of responses to integral OMPs in humans emphasizes the importance of this subclass and points to the value of maintaining conformational epitopes from integral membrane proteins in vaccine formulations. Expand
Exploring the proteome of meningococcal outer membrane vesicle vaccines
TLDR
Proteomic analysis, especially when combined with detailed knowledge of meningococcal population structures, represents a powerful tool in the development of vaccines against this important pathogen. Expand
Neisseria meningitidis antigen NMB0088: sequence variability, protein topology and vaccine potential.
TLDR
According to the results, the recombinant NMB0088 protein may represent a novel antigen for a vaccine against meningococcal disease, and results from the variability study should be considered for designing a cross-protective formulation in future studies. Expand
Identification of vaccine antigens using integrated proteomic analyses of surface immunogens from serogroup B Neisseria meningitidis.
TLDR
An integrated proteomic strategy to identify proteins from N. meningitidis with desirable properties for inclusion in subunit vaccines against bacterial meningitis is presented and provides a generic 2-D gel-based platform for the discovery of vaccine candidates against other bacterial infections. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 72 REFERENCES
Rapid characterization of outer‐membrane proteins in Neisseria lactamica by SELDI–TOF‐MS (surface‐enhanced laser desorption ionization–time‐of‐flight MS) for use in a meningococcal vaccine
TLDR
The findings of this work indicate that SELDI–TOF‐MS is a useful tool for the rapid optimization of OMP production in industrial fermentation processes and can be adapted as a Process Analytical Technology (http://www.fda.gov/cder/OPS/PAT). Expand
Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
TLDR
Investigation of the properties of OMV vaccines made from five different subgroup III serogroup A meningococcal strains grown in a synthetic medium with low iron content finds the strongest IgG responses were directed against PorA, and the vaccines induced antibodies with high SBA and opsonophagocytic activity. Expand
The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.
TLDR
"Tailor-made" vaccines, focusing on the sub-capsular antigens may also be considered for use in sub-Saharan Africa for the prevention of the recurrent outbreaks by serogroups A and W135 meningococci. Expand
Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man.
TLDR
Both the group B polysaccharide and the outer membrane protein are immunogenic in man when presented as a complex and that the complex warrants further testing and development as a vaccine against group B meningococcal disease. Expand
Immunopotentiating Ability of Neisserial Major Outer Membrane Proteins Use As an Adjuvant for Poorly Immunogenic Substances and Potential Use in Vaccines
  • L. Wetzler
  • Chemistry, Medicine
  • Annals of the New York Academy of Sciences
  • 1994
TLDR
Purified meningococcal group C capsular polysaccharide (CPS) was used as a test antigen to measure the potential adjuvant properties of the neisserial OMP and induced significant immune response. Expand
Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans.
TLDR
Two Neisseria meningitidis vaccines provided active protection in mice against mucin-enhanced killing by group B type 2 meningococci and induced good titers of type-specific bactericidal and hemagglutinating antibodies in rabbits. Expand
Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine.
TLDR
The experimental serogroup B meningococcal vaccine was found safe for human use and induced a bactericidal immune response in mice against five of the six wild type strains, which served as donors for the various por A genes. Expand
Proteome analysis of Neisseria meningitidis serogroup A
TLDR
A two‐dimensional gel electrophoresis protein map of the serogroup A strain Z4970, a clinical isolate classified as ancestral to several pandemic waves, is described, believed to be the first systematically annotated proteomic map for N. meningitidis. Expand
Immunogenicity of Outer Membrane Proteins in a Lipopolysaccharide-Deficient Mutant of Neisseria meningitidis: Influence of Adjuvants on the Immune Response
TLDR
It is demonstrated that the immunogenicity of meningococcal LPS-deficient OMCs can be restored by using less toxic adjuvants, which opens up new avenues for development of vaccines against meningitis disease. Expand
Purification and proteomic analysis of outer membrane vesicles from a clinical isolate of Leptospira interrogans serovar Copenhageni
TLDR
These studies indicate that purified OMVs are highly compatible with proteomics technologies including 2‐DE and intact mass proteomics using LC‐MS+ that facilitates definition of actual molecular masses of intact outer membrane proteins, and heterogeneity associated with them. Expand
...
1
2
3
4
5
...